Table 3 Baseline characteristics of the propensity score-matched population

Age (years)

72 ± 9

73 ± 8

7.1

Male sex

67.2%

68.0%

1.8

Body mass index (kg/m²)

24.3 ± 3.7

24.3 ± 3.8

1.5

Smoking

26.1%

28.5%

5.4

Hypertension

88.8%

88.2%

1.9

Dyslipidemia

96.3%

96.0%

1.3

Chronic kidney disease

56.0%

54.1%

3.8

eGFR (ml/min/1.73 m²)

60 ± 21

60 ± 22

2.4

Chronic heart failure

19.4%

19.1%

0.9

HFrEF

4.5%

4.3%

1.1

 (missing data)

0.7%

0.7%

0.8

LVEF (%)

61 ± 12

61 ± 11

4.8

 (missing data)

10.4%

10.9%

1.6

Atrial fibrillation

11.2%

12.5%

4.1

Coronary artery disease

68.7%

68.6%

0.2

 (missing data)

0.0%

0.0%

0.0

Stroke

14.9%

15.8%

2.4

HbA1c (%)

7.7 ± 1.3

7.7 ± 1.6

0.4

 IFCC units (mmol/mol)

61 ± 14

61 ± 17

0.4

 (missing data)

0.0%

0.0%

0.0

SGLT2 inhibitor use

 Empagliflozin

37.3%

–

–

 Dapagliflozin

18.7%

–

–

 Canagliflozin

14.9%

–

–

 Other SGLT2 inhibitors

29.1%

–

–

Aspirin use

80.6%

79.5%

2.7

 (missing data)

0.0%

0.0%

0.0

P2Y12 inhibitor use

88.1%

88.9%

2.6

 (missing data)

0.0%

0.0%

0.0

Cilostazol use

28.8%

28.5%

0.5

 (missing data)

1.5%

1.3%

1.4

Anticoagulant use

20.1%

21.2%

2.5

 (missing data)

0.0%

0.0%

0.0

Statin use

84.2%

83.2%

2.7

 (missing data)

0.7%

1.3%

5.3

CLTI

25.4%

27.9%

5.8

Ankle-brachial index

0.58 ± 0.24

0.58 ± 0.24

2.0

 (missing data)

1.5%

1.4%

1.1

Vessel diameter (mm)

5.0 ± 0.9

5.0 ± 0.9

0.4

 (missing data)

0.0%

0.0%

0.0

Lesion length (cm)

14.6 ± 9.4

14.3 ± 10.1

3.3

 (missing data)

0.0%

0.0%

0.0

Severe calcification

9.7%

10.0%

1.1

 (missing data)

0.0%

0.0%

0.0

Chronic total occlusion

33.6%

31.1%

5.4

 (missing data)

0.0%

0.0%

0.0

Drug coated balloon use

 IN.PACT Admiral

76.9%

76.6%

0.6

 Lutonix

23.1%

23.4%

0.6